Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of Elcubragistat in Healthy Men
NCT05201092Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Jan 2022
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABX-1431 in post-traumatic stress disorder (PTSD), focal epilepsy and multiple sclerosis (MS), sponsored by Lundbeck. Primary endpoints: Cumulative Percent Recovery of Radioactivity in Urine, Cumulative Percent Recovery of Radioactivity in Faeces and 9 more. Started Jan 2022; status: completed.
02
Drugs
ABX-1431
03
Conditions
post-traumatic stress disorder (PTSD)focal epilepsymultiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05201092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201092.